Literature DB >> 21173999

A prospective study of an aggressive warfarin dosing algorithm to reach and maintain INR 2 to 3 after heart valve surgery.

Karina Meijer1, Yang-Ki Kim, Donna Carter, Sam Schulman.   

Abstract

Good anticoagulation control in patients during the first months after heart valve surgery is important to prevent thrombotic complications. This is difficult to achieve, partly because the sensitivity to warfarin decreases progressively during approximately three months after valve surgery. A recently developed, simple but aggressive algorithm might improve anticoagulation control in this patient group. It was the objective of this study to evaluate the level of anticoagulation control when a specialised anticoagulation clinic changed from empirical dosing to the use of this new algorithm. In a before-and-after design, a cohort of consecutive patients managed with a new, aggressive dosing algorithm ('Algorithm cohort') was compared to a 'Retrospective cohort' of similar patients dosed empirically. Primary endpoint was individual time in therapeutic range (ITTR) during the first three months of warfarin therapy. Secondary endpoints included proportion of extreme International Normalised Ratio (INR) results, thrombotic and bleeding complications. Ninety-eight patients were included in the Algorithm cohort, 94 of whom were warfarin-naïve. Two hundred patients were included in the Retrospective cohort. Mean ITTR was 60.1% in the Algorithm cohort versus 48.7% in the Retrospective cohort (p <0.001). Patients in the Algorithm cohort spent 0.5% of time at an INR >5, versus 0.2 % in the Retrospective cohort. There was no major bleeding in either cohort; one patient in each cohort had a thrombotic complication. We demonstrate an improvement of the level of anticoagulation control with the use of a condition-specific, aggressive algorithm, as compared to standard dosing, in patients after heart valve surgery.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21173999     DOI: 10.1160/TH10-05-0324

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  4 in total

1.  Treatment of venous thromboembolism - effects of different therapeutic strategies on bleeding and recurrence rates and considerations for future anticoagulant management.

Authors:  Bastian Hass; Jayne Pooley; Adrian E Harrington; Andreas Clemens; Martin Feuring
Journal:  Thromb J       Date:  2012-12-31

2.  Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trial.

Authors:  Antonio J Carcas; Alberto M Borobia; Marta Velasco; Francisco Abad-Santos; Manuel Quintana Díaz; Carmen Fernández-Capitán; Nuria Ruiz-Giménez; Olga Madridano; Pilar Llamas Sillero
Journal:  Trials       Date:  2012-12-13       Impact factor: 2.279

3.  Identification of clinical factors predicting warfarin sensitivity after cardiac surgery.

Authors:  Karen Tyson; Nevil Hutchinson; Sian Williams; Greg Scutt
Journal:  Ther Adv Drug Saf       Date:  2018-06-05

4.  An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in Spanish patients with thromboembolic disease.

Authors:  Alberto M Borobia; Rubin Lubomirov; Elena Ramírez; Alicia Lorenzo; Armando Campos; Raul Muñoz-Romo; Carmen Fernández-Capitán; Jesús Frías; Antonio J Carcas
Journal:  PLoS One       Date:  2012-07-20       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.